Slides
Page 1
FY2025 Result Presentation One of INDIA’S LARGEST Differentiated Diagnostic Service Provider May 2025
Page 2
Krsnaa Diagnostics Limited
Page 3
Financial Performance ABOUT THE COMPANY 180 CT/ MRI Centres Krsnaa Diagnostics is one of the fastest growing and differentiated diagnostic service provider with services including radiology, pathology and tele-radiology Provides quality and inclusive diagnostic services at disruptive rates across various segments with a focus on Public Private Partnership model 67 Million+ Patients Served Since Inception 3,500+ Patient Collection Centres 117 Pathology Labs 18 States/ UT Presence in India One of India’s largest tele-radiology reporting hubs with the capability to scale the process of X-rays, CT scans and MRI scans and serves patients in remote locations The workforce comprises 350+ radiologists, 100+ pathologists, and over 3,000 qualified professionals, including clinicians, technicians and operators 2
Page 4
Krsnaa Diagnostics Financial- At a Glance FY25 Financial Performance INR in mn except EPS, NABL & NABH Revenue 7,172 6,196 16% EBIDTA 1,958 1,466 34% EBIDTA Margin 27% 24% 370 bps PAT 776 568 37% PAT Margin 11% 9% 165 bps FY25 FY24 GrowthParticulars EPS 23.6 17.3 36% No. of Patient Served 19.2 15.6 23% No. of Test performed 61 44 38% NABL Accreditation 51 21 143% NABH Accreditation 31 22 41% FY25 FY24 GrowthParticulars • Achieving 16% YoY Revenue Growth, 34% YoY EBITDA Strengthening & 37% YoY improvement in PAT, on account of improved footfalls across our centers and enhanced operational efficiency • In FY25, patient and no of tests increased by ~3.6 million and ~ 17 million 3
Page 5
Krsnaa Diagnostics Financial- At a Glance Growth Prospects Radiology Pathology 143 158 180 FY25 FY27E FY27P CT Centre 362 608 875 1,673 4,000 10,000 Q1FY25 Q2FY25 Q3FY25 Q4FY25 FY27E FY27P No. of Touch Points Note: E-Estimates are based on order book in hand & subject to site handover from respective authorities; P-Projected, are based on future opportunities. 117 118 150 FY25 FY27E FY27P Laboratory 37 60 75 FY25 FY27E FY27P MRI Centre 3,478 3,741 5,000 FY25 FY27E FY27P Collection Centres Retail 4
Page 6
Krsnaa Diagnostics Financial- At a Glance Growth Strategy Profitability Driving profitability through cost leadership Awareness Integrated Diagnostic services (Radiology & Pathology) to underserved & unpenetrated markets at most affordable prices Retail Presence Building the Retail business by leveraging our presence and existing infrastructure, tapping into the rising demand for quality diagnostic services in these regions Expansion Continue to enhance our presence across different geographies through organic and inorganic growth Integrated Diagnostics Continue to enhance our presence across different verticals including Radiology, Teleradiology, Pathology & Retail Bidding & Winning Tenders Tap the growing and underpenetrated diagnostic market by participating in new PPP tender 5
Page 7
Competitive Advantages
Page 8
Krsnaa Diagnostics Financial- At a Glance Driving Excellence Through Quality We are committed to delivering superior quality as our benchmark and proudly served ~ 20 mn patients in FY25, driven by our continuous focus on excellence 7 National Accreditation Board for Hospitals & Healthcare Providers 31 National Accreditation for Board of testing's & Calibration Laboratories 51 India’s 1st NABH Accredited Tele-Radiology Hub India’s 1st CAP Accredited Lab at Government Facility
Page 9
Krsnaa Diagnostics Financial- At a Glance Our Pricing- “Everyone Can Afford” 8 • Krsnaa Diagnostics offers high quality diagnostics services at competitive prices • Well placed to withstand any industry price caps as well pricing pressure on tests Segment Test Competition 1 Competition 2 Competition 3 Krsnaa % lower from competitors Radiology CT Brain 4,500 4,500 3,500 880 (75)% Radiology MRI Brain 8,000 8,250 7,000 1,340 (81)% Pathology CBC 250 250 200 37 (82)% Pathology Blood Sugar 85 80 70 20 (71)% Pathology Thyroid 500 550 550 55 (90)% Pathology Vitamin D 1,500 1,250 1,450 153 (89)% Pathology Vitamin B12 1,000 1,100 1,300 69 (95)% Pathology HbA1C 550 440 400 49 (88)% Note: Above mentioned are examples from our comprehensive test lists for illustration purpose only and referenced from publicly available information
Page 10
Krsnaa Diagnostics Financial- At a Glance PAN India Presence 31% 19% 36% 14% West South North East Well Diversified Regional Revenue Mix FY2025 9 India map for representation only and not to scale
Page 11
Industry Opportunity
Page 12
Krsnaa Diagnostics Financial- At a Glance Indian diagnostics industry Diagnostics service under-penetrated 21 19 11 17 12 19 10 9 2 1 Diagnostic test per year per capita Share of diagnostics in healthcare 6% 20% 35% 70% Share of Diagnostics Sector in Healthcare Share of Diagnostics Cost in modern healthcare bill Share of Diagnostics cost in Critical Ailments % Decisions based on Diagnostics test ▪ Despite having the world's largest population, India's diagnostics industry remains under-penetrated—with one of the lowest diagnostics access levels globally, lagging behind even other developing nations such as Brazil and Saudi Arabia ▪ The sector is poised for strong growth, with a projected CAGR of 14% over FY23–28E ▪ In India, there is a mismatch between the economic importance of diagnostics in actual medical treatment and its relatively small share (6%) in the country’s overall healthcare market ▪ The Government of India (GoI) estimates that diagnostics accounts for 10% of the out-of-pocket expenditure at public healthcare set ups that often lack modern diagnostics offerings 11Source: Industry data, Philip Capital Sector Report
Page 13
Krsnaa Diagnostics Financial- At a Glance Opportunity in PPP The increasing adoption of PPPs across states and UTs presents significant opportunities for growth 12 01 The FDSI scheme aims to establish 2,000 radiology centers, with the objective of installing one CT scanner in every district health center—or ensuring access to one scanner per 750,000 people 04 For radiology services, only 19 out of 36 States and UTs have adopted the PPP model to offer free diagnostic services. 02 The Government emphasized the necessity of public-private partnerships (PPP) to achieve self-reliance in India's healthcare sector 05 The Indian government plans to set up Day Care Cancer Centers in all district hospitals over the next three years 03 For pathology services, only 12 out of 36 States and UTs have adopted the PPP model to deliver free diagnostic services 06 State-level funding for free diagnostic services has grown at a faster pace than the overall diagnostics industry Source: Industry data, Philip Capital Sector Report
Page 14
Krsnaa Diagnostics Financial- At a Glance Opportunity in Retail Growth Potential • India’s diagnostics market is projected to grow from $13 billion to $25 billion by FY28E • Two-thirds of diagnostic tests are conducted outside metro cities, underscoring the significant untapped potential for organized players to expand their reach NCD Surge • The growing prevalence of non-communicable diseases (NCDs) in India provides significant growth opportunities, both in volume and value, for the diagnostics industry. • NCD related deaths in India is expected to rise to 70% by 2030 Preventive Testing • Preventive diagnostics have experienced a strong CAGR of 17% over the past five years, reflecting growing awareness and demand • The share of wellness services is expected to rise to 12% of the total pathology market. 01 02 03 13Source: Industry data, Philip Capital Sector Report
Page 15
Krsnaa Retail - RPL
Page 16
Krsnaa Diagnostics Financial- At a Glance Krsnaa Retail - RPL 15 Krsnaa is well-positioned to continue offering highly competitive pricing, reinforcing its leadership as one of the most value-driven service providers in the industry Krsnaa Retail Network Integrated Diagnostics B2B Collaboration Specialised Test • Leveraging existing infrastructure for Radiology & Pathology both for better patient care • Capitalizing on current infrastructure for strategic growth • Focusing on states where we are largely present due to our PPP Projects` • Service portfolio of over 3,200 diagnostic tests across multiple geographies. • Provide services for Specialties such as Gynecology, Orthopedics, and Oncology. • Partnership with Hospitals, nursing homes and laboratories. • Presently serving more than 600 B2B labs, hospitals and nursing homes • Target to expand to ~3,500 by FY27E • Focuse on increasing our presence in 4 states i.e. Maharashtra, Assam, Odisha and Punjab • Current exclusie network of 250 centres • Target to expand retail network to 700 by FY27E
Page 17
Krsnaa Diagnostics Financial- At a Glance Growth in Retail Business 16 © GeoNames, Microsoft, TomTom Powered by Bing Retail Network Key Geographies Maharashtra Punjab Assam Odisha 362 608 875 1,673 Q1 Q2 Q3 Q4 Total Touch Points (Count) 246 267 798 “Within a year, touch points increased by 4X across 4 states” India map for representation only and not to scale
Page 18
Krsnaa Diagnostics Financial- At a Glance Foray into Retail 17 IN-SHOP BRANDING
Page 19
Krsnaa Diagnostics Financial- At a Glance Foray into Retail 18 PREVENTIVE HEALTHCARE - WELLNESS PACKAGES FOR ALL
Page 20
Krsnaa Diagnostics Financial- At a Glance Foray into Retail HEALTHCHECKUP CAMP/AWARENESS 19
Page 21
Krsnaa Diagnostics Financial- At a Glance Foray into Retail 20 KBA-FOFO/FOCO CENTRE
Page 22
Financial Performance RPL - Branding & Awareness Initiatives MediFest Conference in an Association with Indian Medical Association (IMA) Continuous Medical Education (CME) Conference- Advancement in Image Diagnostics Krsnaa Retail Premier League in an Association with Indian Medical Association (IMA) 21
Page 23
Krsnaa Diagnostics Financial- At a Glance Awards & Accolades Best Diagnostic Lab Chain of the year (West) Leading HR Transformation Award 22
Page 24
Financial Performance
Page 25
Krsnaa Diagnostics Financial- At a Glance FY25 - At a Glance FY25 7,172 FY24 6,196 Revenue from operation 16% FY25 1,958 FY24 1,466 EBIDTA 34 % FY25 776 FY24 568 PAT 37% FY25 27% FY24 24% EBIDTA Margin 370 bps FY25 11% FY24 9% PAT Margin 165 bps FY25 23.6 FY24 17.3 Earning Per Share 36% EBIDTA & EBIDTA Margin are before CSR & ESOP 24 In mn
Page 26
Krsnaa Diagnostics Financial- At a Glance Q4FY25 – At a Glance In mn Q4FY25 1,861 Q4FY24 1,663 Revenue from operation 12% Q4FY25 542 Q4FY24 446 EBIDTA 21% Q4FY25 207 Q4FY24 187 PAT 11% Q4FY25 29% Q4FY24 27% EBIDTA Margin 230 bps Q4FY25 11% Q4FY24 11% PAT Margin 1 bps Q4FY25 6.3 Q4FY24 5.7 Earning Per Share 11% EBIDTA & EBIDTA Margin are before CSR & ESOP 25
Page 27
Krsnaa Diagnostics Financial- At a Glance Centre Maturity Profile Notes: 1. Net Block % is calculated as on the year ended 31st March 2025 2. Maturity is on the basis of the project start date 3. Return on Capital Employed calculated as (EBIT including Other Income / (Total Asset - Current Liabilities)) Krsnaa Younger Portfolio Continues to Mature with Promising Future 26% Net Block 2% ROCE 33% Net Block 24% ROCE 42% Net Block 35% ROCE 26
Page 28
Krsnaa Diagnostics Financial- At a Glance Consolidated Financial Performance FY 25 Q3 FY 25 Q4 FY 25 Q4 FY 24 FY 24Particulars Amount % Amount % Amount % Amount % Amount % Revenue from operations 1,861 1,745 1,663 7,172 6,196 Expenses Cost of Material Consumed 415 22% 399 23% 430 26% 1,693 24% 1,410 23% Employee benefits expense 320 17% 348 20% 324 19% 1,327 19% 1,105 18% Fees to hospitals and others 174 9% 136 8% 94 6% 607 9% 654 11% Other expenses 410 22% 397 23% 374 22% 1,587 22% 1,560 25% Total Expenses 1,319 71% 1,280 73% 1,222 73% 5,214 73% 4,730 76% EBITDA Before CSR & ESOP 542 29% 466 27% 441 27% 1,958 27% 1,466 24% CSR and ESOP 12 1% 15 1% 4 0% 57 1% 24 0% EBITDA 530 29% 451 26% 437 26% 1,901 27% 1,442 23% Less: Finance costs 68 4% 61 4% 73 4% 247 3% 165 3% Less: Depreciation 220 12% 227 13% 181 11% 883 12% 745 12% Add: Other income 44 2% 92 5% 43 3% 255 4% 168 3% PBT 286 15% 255 15% 226 14% 1,027 14% 700 11% Tax 79 4% 61 4% 39 2% 251 4% 132 2% PAT 207 11% 194 11% 187 11% 776 11% 568 9% In mn 27
Page 29
Krsnaa Diagnostics Financial- At a Glance Consolidated Financial Performance Liabilities Mar 31, 2025 Mar 31, 2024 Equity Equity share capital 161.45 161.45 Other equity 8,666.25 7,936.57 Total equity 8,827.70 8,098.02 Liabilities Non-current liabilities Borrowings 185.04 55.00 Lease Liabilities 286.52 363.81 Other financial liabilities 208.29 205.59 Provision 28.61 17.75 Deferred Tax Liabilities (Net) 225.91 164.30 Other non-current liabilities - - Total non-current liabilities 934.37 806.45 Current liabilities Financial liabilities Borrowings 1,470.38 1,012.21 Lease Liabilities 93.33 166.86 Trade payables 971.27 823.18 Other financial liabilities 371.14 678.19 Other current liabilities 54.17 91.95 Provision 55.77 42.26 Current Tax Liabilities (Net) 37.82 - Current liabilities 3,053.88 2,814.66 Total Liabilities 3,988.25 3,621.11 Total Equity and Liabilities 12,815.95 11,719.13 Assets Mar 31, 2025 Mar 31, 2024 Non-current assets Property, plant and equipment 6,674.34 6,447.21 Capital work-in-progress 29.63 98.45 Intangible assets 29.49 24.34 Financial assets Investments 315.42 2.91 Other financial assets 1,182.77 326.64 Deferred tax asset (net) 33.33 16.31 Other non-current assets 406.25 591.41 Total non-current assets 8,671.23 7,507.27 Current assets Inventories 294.76 358.07 Financial assets Trade receivables 2,777.45 1,762.92 Cash and cash equivalents 38.46 23.75 Bank balances other than cash and cash equivalent 645.90 1,728.10 Other financial assets 282.89 214.35 Other current assets 105.26 124.67 Total current assets 4,144.72 4,211.86 Total Assets 12,815.95 11,719.13 (INR In Mn) 28
Page 30
Contact Information This presentation contains statements that are “forward looking statements” including, but without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to Krsnaa Diagnostics’ future business developments and economic performance. While these forward looking statements indicate our assessment and future expectations concerning the development of our business, a number of risks, uncertainties and other unknown factors could cause actual developments and results to differ materially from our expectations. These factors include, but are not limited to, general market, macro-economic, governmental and regulatory trends, movements in currency exchange and interest rates, competitive pressures, technological developments, changes in the financial conditions of third parties dealing with us, legislative developments, and other key factors that could affect our business and financial performance. Krsnaa Diagnostics undertakes no obligation to publicly revise any forward looking statements to reflect future / likely events or circumstances. For further information please contact: Krsnaa Diagnostics Vivek Jain, Investor Relation Head head.investor@krsnaa.in Contact: +91 74107 00645 Contact Information 29